Recent estimates cite the risk-adjusted cost of bringing a new drug to approval to be north of $2.5 billion. This is a staggering amount, particularly when less than 10 percent of newly innovated therapeutics survive the clinical development process. Indeed, drug development is fraught with high costs and low …

A new study authored by Foundation Medicine scientists was published in the journal, The Oncologist, and provides clinical evidence that nearly all advanced esophageal cancers harbor genomic mutations that can be targeted with current or emerging drug therapies. Researchers at Foundation Medicine performed …

The Blueprint for Drug/Diagnostic Development: Facilitating Development and Use of Curated Genetic Databases forum was held this morning at The Mayflower in Washington D.C. Roman Yelensky, Ph.D., vice president, biomarker and companion diagnostic development at Foundation Medicine represented the company in the first …

A key focus for all of us here at Foundation Medicine is to show how companion diagnostic development can deliver significant patient benefits, health care cost savings and value based payer coverage. On August 18 – 20, Matthew Hawryluk, Ph.D., vice president, corporate and business development at Foundation Medicine …

A research brief published today in the online edition of the journal Cancer Discovery, provides clinical evidence for the utility of comprehensive genomic profiling in matching patients to targeted therapy clinical trials. A female patient with advanced soft tissue sarcoma widely metastatic to the lungs had a tumor …

In January of this year, President Barack Obama said that personalized medicine “gives us one of the greatest opportunities for new medical breakthroughs that we have ever seen.” We couldn’t agree more! In an effort to further educate representatives on Capitol Hill, our CEO, Michael Pellini, MD, participated in a …

Foundation Medicine’s chief executive officer, Michael Pellini, M.D., joined a panel discussion today at the BIO 2015 International Convention titled “Transforming Diagnostics With Innovative Technologies: Potential and Pitfalls.” The panel, which was moderated by Jo Natauri, a partner at Goldman Sachs, also featured …

Imagine you or a loved one had an advanced biliary tract cancer – tumors that originate in the bile ducts or gallbladder – and you learn that all of your treatment options have been exhausted. Where do you go from there? New data presented at the 2015 ASCO Annual Meeting, including promising clinical outcomes in …

Today at ASCO, our collaborators from the University of California, Irvine presented groundbreaking new data demonstrating the role of certain genomic alterations, known as MET exon 14 (METex14), as drivers of growth of non-small cell lung cancer (NSCLC). These findings identify a unique subset of patients likely to …

Of course, we say “yes!” Today at the Annual Meeting, our collaborators from the University of Texas MD Anderson Cancer Center (MDACC) and Sarah Cannon Research Institute at HealthOne, presented exciting new data demonstrating that matching patients to targeted therapies based on the unique molecular profile of the …